Psychedelic Stocks

Study Finds That Psychedelics Can Alter Core Metaphysical Beliefs

A new study has found that psychedelic substances can alter an individual’s core beliefs about the nature of free will, consciousness and reality. The study’s findings were reported in the “Scientific Reports” journal.

The researchers’ objective was to find out whether psychedelics had the capacity to change a person’s core metaphysical beliefs, because the drugs can induce spiritual encounters and transformative experiences. Metaphysical beliefs are ideas about reality’s fundamental nature.

The study was carried out by a team of researchers led by Christopher Timmermann, who examined the metaphysical beliefs of participants before and after they had used psychedelics. The researchers also assessed how these changes may have affected the participants’ mental health.

For their research, the team recruited more than 800 participants who planned to attend a ceremony where they could use psychedelics such as DMT, ayahuasca and psilocybin. The participants came from a number of countries, with the majority being from the United States and the United Kingdom. Before they attended the ceremony, each participant had to complete a survey that included measures of determinism, free will and metaphysical beliefs, i.e., dualism, idealism, materialism/physicalism. The participants completed the same survey four weeks after the ceremony, then again six months later.

The researchers classified the participants based on their beliefs at baseline, coming up with four groupings: materialists, idealists, dualists and mixed/none. They used these categories to better assess how the views of each participant changed.

Their findings show that the beliefs of the participants swayed from materialism after the ceremony, with the researchers noting that this change was significant at both the four-week and six-month follow-ups. They also found that participants who were hard materialists shifted to none/mixed or hard-dualism after their experiences on psychedelics, noting that switching from hard materialism was linked to better well-being.

The researchers also found that the shift from materialism was strongest among participants who hadn’t used psychedelics before. In addition to this, the survey found increases in the belief in a predetermined future and fate, highlighting that while these increases were present for all during the first follow-up, they were maintained at the second follow-up among respondents who were first-time users of the substances.

In their report, the researchers note that their findings suggest that psychedelics have the potential to alter some of the most influential and deep-seated human beliefs.

Other researchers who were part of the study include Fernando E. Rosas, Leor Roseman, Chris Letheby, Hannes Kettner and Robin L. Carhart-Harris.

Such research findings suggest that any psychedelic-based formulations made by entities such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) could have beneficial effects beyond the primary indication for which those medicines were prescribed, and that would be good for patients.

NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

4 days ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

1 week ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central…

4 weeks ago

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of…

4 weeks ago